Key Points
- Director Roberto Mignone sold 367,600 Teva shares at an average price of $39.06, generating approximately $14.36 million in proceeds. The transaction was disclosed in an SEC filing.
- Teva shares opened at $39.56, near their 12-month high of $40.79, with a market capitalization of about $46.1 billion. The company reported quarterly revenue of $4.14 billion and earnings of $0.02 per share.
- Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $43.10; UBS, Barclays and Piper Sandler recently raised their targets.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) insider Brian Savage sold 7,342 shares of the stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the sale, the insider directly owned 8,500 shares in the company, valued at $330,225. This trade represents a 46.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Teva Pharmaceutical Industries Stock Down 1.3%
TEVA stock opened at $39.56 on Wednesday. Teva Pharmaceutical Industries Ltd. has a one year low of $18.21 and a one year high of $40.79. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. The firm's fifty day moving average is $35.73 and its 200 day moving average is $33.65. The firm has a market cap of $46.10 billion, a PE ratio of 65.93, a P/E/G ratio of 4.99 and a beta of 0.87.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The business had revenue of $4.14 billion during the quarter. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.94 EPS for the current year.
Key Headlines Impacting Teva Pharmaceutical Industries
Here are the key news stories impacting Teva Pharmaceutical Industries this week:
- Positive Sentiment: Teva reported new Phase 3 SOLARIS data for investigational once-monthly olanzapine long-acting injectable (LAI) TEV-749 in adults with schizophrenia. The program could strengthen Teva’s central-nervous-system pipeline and provide a future growth opportunity if approved. Teva Pharmaceutical Industries Why Is It Back In The Spotlight
- Positive Sentiment: At Psych Congress 2026, Teva presented additional analyses from the SOLARIS trial and new data on UZEDY®, its long-acting schizophrenia treatment using Medincell’s drug-delivery technology. The updates support investor interest in Teva’s long-acting injectable franchise, although they do not yet represent regulatory approval. Medincell Partner Teva Presented New Data
- Neutral Sentiment: Teva’s U.S. All Stars Conference presentation transcript may provide additional commentary on its pipeline and business outlook, but the available report does not identify a specific new catalyst or material change in guidance. Teva Presents at U.S. All Stars Conference Transcript
- Negative Sentiment: Director Roberto Mignone sold 367,600 Teva shares for approximately $14.36 million. The large transaction, disclosed after Teva’s recent gains, may raise concerns about insider confidence and add near-term selling pressure. SEC Filing for Roberto Mignone Share Sale
- Negative Sentiment: Insider Brian Savage separately sold 7,342 shares valued at about $285,000, reducing his ownership by 46.35%. While smaller than the director’s sale, the additional insider transaction reinforces the negative sentiment around near-term trading. SEC Filing for Brian Savage Share Sale
Analyst Upgrades and Downgrades
Several analysts have commented on the company. Leerink Partners started coverage on Teva Pharmaceutical Industries in a report on Wednesday, September 9th. They issued an "outperform" rating and a $45.00 price objective on the stock. Weiss Ratings lowered shares of Teva Pharmaceutical Industries from a "hold (c)" rating to a "hold (c-)" rating in a report on Tuesday, September 8th. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, August 12th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Finally, UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a "buy" rating in a research report on Friday, September 4th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $43.10.
Read Our Latest Research Report on TEVA
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of TEVA. Bullseye Investment Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $68,000. Sequoia Financial Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 12.5% during the second quarter. Sequoia Financial Advisors LLC now owns 190,940 shares of the company's stock worth $6,469,000 after purchasing an additional 21,240 shares in the last quarter. National Pension Service boosted its position in shares of Teva Pharmaceutical Industries by 4.9% during the second quarter. National Pension Service now owns 2,406,013 shares of the company's stock worth $81,516,000 after buying an additional 112,357 shares during the period. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at $33,799,000. Finally, IFP Advisors Inc grew its stake in shares of Teva Pharmaceutical Industries by 1.1% in the second quarter. IFP Advisors Inc now owns 143,876 shares of the company's stock valued at $4,875,000 after buying an additional 1,532 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.
Teva's specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
